1. Home
  2. REGN vs RCL Comparison

REGN vs RCL Comparison

Compare REGN & RCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • RCL
  • Stock Information
  • Founded
  • REGN 1988
  • RCL 1968
  • Country
  • REGN United States
  • RCL United States
  • Employees
  • REGN N/A
  • RCL N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • RCL Marine Transportation
  • Sector
  • REGN Health Care
  • RCL Consumer Discretionary
  • Exchange
  • REGN Nasdaq
  • RCL Nasdaq
  • Market Cap
  • REGN 63.4B
  • RCL 63.0B
  • IPO Year
  • REGN 1991
  • RCL N/A
  • Fundamental
  • Price
  • REGN $490.28
  • RCL $257.15
  • Analyst Decision
  • REGN Buy
  • RCL Strong Buy
  • Analyst Count
  • REGN 23
  • RCL 18
  • Target Price
  • REGN $891.17
  • RCL $273.50
  • AVG Volume (30 Days)
  • REGN 1.5M
  • RCL 1.8M
  • Earning Date
  • REGN 04-29-2025
  • RCL 07-24-2025
  • Dividend Yield
  • REGN 0.36%
  • RCL 0.95%
  • EPS Growth
  • REGN 16.49
  • RCL 60.94
  • EPS
  • REGN 39.43
  • RCL 12.30
  • Revenue
  • REGN $14,085,700,000.00
  • RCL $16,756,000,000.00
  • Revenue This Year
  • REGN N/A
  • RCL $10.32
  • Revenue Next Year
  • REGN $6.97
  • RCL $9.48
  • P/E Ratio
  • REGN $12.43
  • RCL $20.89
  • Revenue Growth
  • REGN 7.52
  • RCL 13.66
  • 52 Week Low
  • REGN $485.00
  • RCL $130.08
  • 52 Week High
  • REGN $1,211.20
  • RCL $277.08
  • Technical
  • Relative Strength Index (RSI)
  • REGN 32.32
  • RCL 65.69
  • Support Level
  • REGN $590.15
  • RCL $232.60
  • Resistance Level
  • REGN $608.17
  • RCL $256.72
  • Average True Range (ATR)
  • REGN 18.79
  • RCL 6.41
  • MACD
  • REGN -3.82
  • RCL 0.15
  • Stochastic Oscillator
  • REGN 3.98
  • RCL 93.75

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About RCL Royal Caribbean Cruises Ltd.

Royal Caribbean is the world's second-largest cruise company, operating 66 ships across five global and partner brands in the cruise vacation industry. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises. The selection of brands in the portfolio allows Royal to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in 2021 and plans to launch its new Celebrity River Cruise brand in 2027.

Share on Social Networks: